Cel Sci (CVM) Cash from Investing Activities (2010 - 2025)
Cel Sci (CVM) posted Cash from Investing Activities of -$5155.0 for Q3 2025, up 84.36% sequentially from -$32954.0 in Q4 2024, and up 73.9% YoY from -$2964.3 in Q3 2024.
Cel Sci (CVM) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Cel Sci has reported Cash from Investing Activities for 15 years, with the latest figure at -$5155.0 in Q3 2025.
- Quarterly Cash from Investing Activities rose 73.9% year-over-year to -$5155.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was -$5155.0 (up 93.23% YoY) and the FY2025 annual result came in at -$38109.0, up 64.74% from the prior year.
- Cash from Investing Activities climbed to -$5155.0 in Q3 2025 per CVM's latest filing, from -$32954.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $6.1 million in Q4 2021 and troughed at -$14.6 million in Q1 2021.
- A 5-year average of -$441375.2 and a median of -$43267.0 in 2022 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 508.12% in 2021, down 2125.73% in 2021.
- Over 5 years, Cash from Investing Activities stood at $6.1 million in 2021, then plunged by 100.88% to -$53580.0 in 2022, then dropped by 21.05% to -$64861.0 in 2023, then soared by 49.19% to -$32954.0 in 2024, then jumped by 84.36% to -$5155.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$5155.0, -$32954.0, and -$19753.0 for Q3 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -5,155.00 |
| Sep 30, 2025 | -5,155.00 |
| Dec 31, 2024 | -32,954.00 |
| Dec 31, 2024 | -32,954.00 |
| Sep 30, 2024 | -19,753.00 |
| Sep 30, 2024 | -19,753.00 |
| Jun 30, 2024 | -23,472.00 |
| Jun 30, 2024 | -23,472.00 |
| Dec 31, 2023 | -64,861.00 |
| Dec 31, 2023 | -64,861.00 |
| Sep 30, 2023 | -10,370.00 |
| Sep 30, 2023 | -10,370.00 |
| Jun 30, 2023 | -196,860.00 |
| Jun 30, 2023 | -196,860.00 |
| Mar 31, 2023 | -111,452.00 |
| Mar 31, 2023 | -111,452.00 |
| Dec 31, 2022 | -53,580.00 |
| Dec 31, 2022 | -53,580.00 |
| Sep 30, 2022 | -16,066.00 |
| Sep 30, 2022 | -16,066.00 |